Search results for "leukemia"

showing 10 items of 976 documents

2α-Hydroxyalantolactone from Pulicaria undulata: activity against multidrug-resistant tumor cells and modes of action.

2020

Abstract Background Sesquiterpene lactones having α-methylene-γ-lactone moiety are promising natural metabolites showing various biological activity. One of the major metabolites isolated from Pulicaria undulata, 2α-hydroxyalantolactone (PU-1), has not been investigated in detail yet. Multidrug resistance (MDR) represents a major obstacle for cancer chemotherapy and the capability of novel natural products to overcoming MDR is of great interest. Purpose Exploring the molecular modes of action for potent natural product metabolites. Methods The resazurin reduction assay was employed to evaluate the cytotoxicity of PU-1 on sensitive and their corresponding drug-resistant cell lines (overexpre…

DNA damagePharmaceutical ScienceApoptosisPulicaria03 medical and health sciencesPhosphatidylinositol 3-Kinases0302 clinical medicineCell Line TumorDrug DiscoveryHumansPI3K/AKT/mTOR pathway030304 developmental biologyPhosphoinositide-3 Kinase InhibitorsPharmacology0303 health sciencesLeukemiaCell growthChemistryCell cycleG2-M DNA damage checkpointMolecular biologyAntineoplastic Agents PhytogenicBlotGene expression profilingG2 Phase Cell Cycle CheckpointsGene Expression Regulation NeoplasticComplementary and alternative medicineApoptosisDrug Resistance Neoplasm030220 oncology & carcinogenesisMolecular MedicineSesquiterpenesDNA DamagePhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct

TRAIL Triggers CRAC-Dependent Calcium Influx and Apoptosis through the Recruitment of Autophagy Proteins to Death-Inducing Signaling Complex

2021

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively kills various cancer cell types, but also leads to the activation of signaling pathways that favor resistance to cell death. Here, we investigated the as yet unknown roles of calcium signaling and autophagy regulatory proteins during TRAIL-induced cell death in leukemia cells. Taking advantage of the Gene Expression Profiling Interactive Analysis (GEPIA) project, we first found that leukemia patients present a unique TRAIL receptor gene expression pattern that may reflect their resistance to TRAIL. The exposure of NB4 acute promyelocytic leukemia cells to TRAIL induces intracellular Ca2+ influx through a calcium rel…

Death Domain Receptor Signaling Adaptor ProteinsautophagyQH301-705.5p62/SQSTM1Autophagy-Related ProteinsApoptosisTretinoin[SDV.CAN]Life Sciences [q-bio]/CancerEndoplasmic ReticulumArticleTNF-Related Apoptosis-Inducing LigandJurkat Cells[SDV.CAN] Life Sciences [q-bio]/CancerHomeostasisHumanscancerBiology (General)ATRASequence Analysis RNAATRA; ATG7; autophagy; cancer; CRAC channels; DISC; leukemia; ORAI1; p62/SQSTM1; resistance to therapyleukemiaGeneral MedicineDISCORAI1Receptors TNF-Related Apoptosis-Inducing Ligand[SDV.AEN] Life Sciences [q-bio]/Food and NutritionCytoprotectionDrug Resistance Neoplasmresistance to therapyCalciumCalcium ChannelsCRAC channelsATG7[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
researchProduct

In vivo fate mapping with SCL regulatory elements identifies progenitors for primitive and definitive hematopoiesis in mice.

2009

10 páginas, 6 figuras.-- et al.

Definitive hematopoiesisEmbryologyMyeloidPopulationConditional mouse modelIn vivo linage and fate tracingEmbryonic DevelopmentStem cell leukemia geneBiology03 medical and health sciencesMice0302 clinical medicineFate mappinghemic and lymphatic diseasesProto-Oncogene ProteinsCRE systemmedicineBasic Helix-Loop-Helix Transcription FactorsAnimalsCell LineageMesodermal blood cell specificationGene Knock-In TechniquesProgenitor celleducationGeneTetracycline systemT-Cell Acute Lymphocytic Leukemia Protein 1Primitive hematopoiesis030304 developmental biology0303 health scienceseducation.field_of_studyMicroscopy ConfocalStem CellsEmbryoFlow CytometryCell biologyHematopoiesisGastrulationHaematopoiesismedicine.anatomical_structureBlood cell precursors030220 oncology & carcinogenesisImmunologyIn vivo lineage markingDevelopmental BiologyMechanisms of development
researchProduct

Can NF-κB Be Considered a Valid Drug Target in Neoplastic Diseases? Our Point of View

2020

Multidrug resistance (MDR), of the innate and acquired types, is one of major problems in treating tumor diseases with a good chance of success. In this review, we examine the key role of nuclear factor-kappa B (NF-κB) to induce MDR in three tumor models characterized precisely by innate or acquired MDR, in particular triple negative breast cancer (TNBC), hepatocellular carcinoma (HCC), and acute myeloid leukemia (AML). We also present different pharmacological approaches that our group have employed to reduce the expression/activation of this transcriptional factor and thus to restore chemo-sensitivity. Finally, we examine the latest scientific evidence found by other groups, the most sign…

Drug targetAntineoplastic AgentsReviewCatalysisNF-κBdrug targetlcsh:ChemistryInorganic Chemistrychemistry.chemical_compoundNeoplasmsMDRmedicineBiomarkers TumorcancerAnimalsHumansMolecular Targeted TherapyPhysical and Theoretical Chemistrylcsh:QH301-705.5Molecular BiologySpectroscopyTriple-negative breast cancerbusiness.industryOrganic ChemistryNF-kappa BCancerMyeloid leukemiaNF-κBGeneral Medicinemedicine.diseaseComputer Science ApplicationsMultiple drug resistanceClinical trialCell Transformation Neoplasticlcsh:Biology (General)lcsh:QD1-999chemistryDrug Resistance NeoplasmHepatocellular carcinomaCancer researchSettore BIO/14 - FarmacologiaDisease SusceptibilitybusinessInternational Journal of Molecular Sciences
researchProduct

The role of drug sequence in therapeutic selectivity of the combination of 5-fluorouracil and cis-platin.

1989

The therapeutic efficacy of 5-fluorouracil (FUra) and cis-dichlorodiamine-platinum (cis-DDP) in mice bearing transplantable leukemia and solid tumors was evaluated using different sequences of combination of these agents. The optimal sequence was cis-DDP administered 24 h after FUra. The administration of FUra at its maximally tolerated dose (MTD) followed 24 h later by low doses of cis-DDP yielded less toxicity and higher response rate against L1210 and colon 26 than the administration of these two agents in the opposite sequence or concurrently at the MTD. The sequence of administration of these two agents was not therapeutically important when the antitumor activity was evaluated against…

DrugCancer Researchendocrine system diseasesLymphomaRatónmedicine.medical_treatmentmedia_common.quotation_subjectPharmacologyThymidylate synthaseDrug Administration ScheduleMiceAntineoplastic Combined Chemotherapy ProtocolsmedicineTumor Cells CulturedAnimalsLeukemia L1210media_commonPharmacologyChemotherapybiologyDose-Response Relationship Drugbusiness.industryThymidylate SynthaseDrug interactionmedicine.diseaseLeukemiaFluorouracilMice Inbred DBAToxicityImmunologyColonic Neoplasmsbiology.proteinFluorouracilCisplatinbusinessmedicine.drugSelective cancer therapeutics
researchProduct

Could resveratrol be a useful drug for the treatment of malignant hemopathies?

2013

Resveratrol is a poly-phenol with many beneficial effects: not only as an antioxidant, anti-inflammatory, and antiatherogenic agent, as well as a platelet aggregation inhibitor, but also as an antiproliferative and proapoptotic factor in various types of cancers. There are reviews about the mechanisms responsible for its effects in leukemia and lymphomas, emphasizing the chemosensitizing role of resveratrol, which allows overcoming the multidrug resistance of cancers. The action of resveratrol occurs preferentially on leukemic cells, and not on the normal ones. In addition, it is one of the few drugs that act on leukemic stem cells. If experimental results are promising, its application in …

DrugCancer Researchmedicine.medical_treatmentmedia_common.quotation_subjectAntineoplastic AgentsPharmacologyResveratrolAntioxidantsPatents as Topicchemistry.chemical_compoundNeoplasmsDrug DiscoveryStilbenesmedicineHumansPharmacology (medical)Antiatherogenic agentmedia_commonbusiness.industryGeneral Medicinemedicine.diseaseAntineoplastic Agents PhytogenicBioavailabilityLeukemiaOncologychemistryResveratrolHematologic NeoplasmsPlatelet aggregation inhibitorDrug Therapy CombinationStem cellbusinessAdjuvantRecent patents on anti-cancer drug discovery
researchProduct

Chemical and biological evaluation of cross-linked halloysite-curcumin derivatives

2020

Abstract Well designed and safe nano drug carrier systems are an important tool in biomedical applications. The combination of two or more drugs has been used in medicine both to enhance the therapeutic effect and to decrease the side effects of drugs. Biocompatible halloysite nanotubes, that possess two different surfaces, are a suitable nanomaterial for a simultaneous carrier and release of two drugs that can exert a synergistic effect against cancer cells. In this study, three curcumin derivatives and doxorubicin were loaded by supramolecular and covalent linkage at the lumen and external surface of the halloysite nanotubes. The obtained multifunctional systems were characterized by seve…

Drugmedia_common.quotation_subjectNanoparticle020101 civil engineering02 engineering and technologyengineering.materialHalloysite0201 civil engineeringchemistry.chemical_compoundGeochemistry and PetrologymedicineDoxorubicinCytotoxicitymedia_commonSettore CHIM/02 - Chimica FisicaHalloysite nanotubes Curcumin derivatives Dual drug delivery Antiproliferative activity Breast cancer cell lines and acute myeloid leukemia cell linesChemistryGeologySettore CHIM/06 - Chimica Organica021001 nanoscience & nanotechnology3. Good healthCancer cellBiophysicsengineeringCurcuminSettore BIO/14 - Farmacologia0210 nano-technologyDrug carriermedicine.drug
researchProduct

Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells

2012

PLoS one 7(7), e40853 (2012). doi:10.1371/journal.pone.0040853

Drugs and DevicesDrug Research and DevelopmentTime Factorsmedicine.drug_classChronic Myeloid LeukemiaIntracellular Spacelcsh:MedicineApoptosisPharmacologyPiperazinesTyrosine-kinase inhibitorHematologic Cancers and Related DisordersCell Line TumorLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesLeukemiasmedicineHumansAnnexin A5Proto-Oncogene Proteins c-abllcsh:ScienceProtein Kinase InhibitorsMyeloproliferative DisordersMultidisciplinaryABLDose-Response Relationship DrugCaspase 3Chemistrylcsh:RBiological activityImatinibHematologyrespiratory tract diseasesDasatinibKineticsPyrimidinesImatinib mesylatePharmacodynamicsBenzamidesImatinib MesylateMedicineATP-Binding Cassette Transporterslcsh:QDrug Screening Assays AntitumorSignal transductionIntracellularResearch ArticleSignal Transductionmedicine.drug
researchProduct

Rapid Expansion of Acute Myeloid Leukemia-Reactive Cytotoxic T Cells from CD8+CD62L+ Blood Lymphocytes of HLA-Matched Healthy Donors In Vitro

2006

Abstract Allogeneic cytotoxic T-lymphocyte (CTL) therapy in acute myeloid leukemia (AML) is hampered by the poor efficiency of growing leukemia-reactive CTLs from healthy donors in vitro. We established an allogeneic mini-mixed lymphocyte-leukemia culture (MLLC) approach by stimulating comparably small numbers (104/well) of CD8+ T cells isolated from healthy donors against irradiated primary AML blasts in 96-well plates. Prior to use, CD8+ T cells were immunomagnetically separated into a CD62L(high)+ subset enriched for naive precursors and central memory cells as well as a CD62L(low)+/negative subset containing effector memory cells. The culture medium contained IL-7, IL-12, and IL-15. Aft…

ELISPOTImmunologyMyeloid leukemiaCell BiologyHematologyHuman leukocyte antigenBiologyBiochemistryHaematopoiesisCTL*Antigenhemic and lymphatic diseasesImmunologyCytotoxic T cellCD8Blood
researchProduct

Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhi…

2014

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease of controversial origin recently recognized as a neoplasm deriving from plasmacytoid dendritic cells (pDCs). Nevertheless, it remains an orphan tumor with obscure biology and dismal prognosis. To better understand the pathobiology of BPDCN and discover new targets for effective therapies, the gene expression profile (GEP) of 25 BPDCN samples was analyzed and compared with that of pDCs, their postulated normal counterpart. Validation was performed by immunohistochemistry (IHC), whereas functional experiments were carried out ex vivo. For the first time at the molecular level, we definitely recognized the cellular derivati…

EXPRESSIONMyeloidCancer ResearchPathologymedicine.medical_specialtyMyeloidCell Cycle; Dendritic Cells; Humans; Leukemia Myeloid Acute; NF-kappa B; Signal Transduction; Gene Expression Profiling; Hematology; Cancer Research; Anesthesiology and Pain MedicineAcuteBiologyCell Cycle; Dendritic Cells; Humans; Leukemia Myeloid Acute; NF-kappa B; Signal Transduction; Gene Expression ProfilingDendritic CellArticleMALIGNANCIESMULTIPLE-MYELOMABlastic plasmacytoid dendritic cell neoplasmBlastic plasmacytoid dendritic cell neoplasm; anti-NF-kB-treatment; GEPGene expressionmedicineHumansNeoplasmanti-NF-kB-treatmentGene Expression ProfilingCell CycleNF-kappa BleukemiaIN-VITRODendritic CellsHematologyBlastic plasmacytoid dendritic cell neoplasmmedicine.diseaseCANCERGEPFACTOR-KAPPA-BLeukemia Myeloid AcuteSettore MED/15 - MALATTIE DEL SANGUEDIFFERENTIATIONAnesthesiology and Pain Medicinemedicine.anatomical_structureLYMPHOID PATHWAYSOncologyCell cultureHEMATODERMIC NEOPLASMImmunohistochemistryCellular modelEx vivoHumanSignal Transduction
researchProduct